NYSE:MRKPharmaceuticals
Merck Weighs mRNA Breakthrough And Revolution Deal Against Oncology Valuation
Merck (NYSE:MRK) and Moderna released five-year clinical data on a personalized mRNA cancer vaccine regimen used with Keytruda in high-risk melanoma.
The follow-up results point to a meaningful improvement in outcomes for skin cancer patients treated in the study.
Separately, Merck is reported to be in advanced discussions to acquire Revolution Medicines, a move connected to its oncology pipeline ahead of key patent expirations.
For you as an investor, this pairs Merck’s core strength in...